This site is intended for U.S. healthcare professionals.

Commercially available test providers for BRAF-mutant mCRC

Explore currently available ctDNA testing for rapid results on BRAF mutation status. These laboratories offer next-generation sequencing (NGS) with both liquid and tissue biopsies.

This information is intended as educational only, is not intended as a complete list of available testing options and is not regularly updated. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. Pfizer is not responsible for any test provider and does not endorse or recommend any particular diagnostic test. The accuracy and results of diagnostic tests vary, and Pfizer shall have no liability arising from such testing. The information provided herein should in no way be considered a guarantee of coverage, reimbursement, availability, or patient assistance. Providers should contact third-party laboratories for information.

FAQs

• Which patients with metastatic colorectal cancer should be tested for BRAF mutations?
• NCCN Guidelines recommend testing all patients with mCRC at initial workup.^1,2 Learn more about how BRAF-mutant mCRC can affect your patients’ prognosis here.

• How does BRAF-mutant metastatic colorectal cancer differ from wild-type mCRC?
• The BRAF gene encodes a receptor in the mitogen-activated protein kinase (MAPK) pathway, and a mutation in the BRAF gene can lead to cancer.³ Learn how BRAF mutations in mCRC affect patient prognosis when compared to wild-type mCRC here.

• Which rapid tests can I use to confirm BRAF mutation status in mCRC?
• Many biomarker testing technologies for BRAF mutations are available. Liquid biopsy for BRAF mutations can be used and combined with tissue biopsy results to confirm the type of mCRC your patient has.^4,5 Learn more about ctDNA testing, PCR sequencing, and IHC testing for BRAF-mutant mCRC here.

References

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 7, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 7, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3. Tabernero J, Ros J, Élez E. Am Soc Clin Oncol Educ Book. 2022;42:254-263.
4. Benavides M, Alcaide-Garcia J, Torres E, et al. ESMO Open. 2022;7(3):100481.
5. Tao XY, Li QQ, Zeng Y. Mol Cancer. 2024;23(1):145.